Search results for " arthritis"

showing 10 items of 629 documents

Heme oxygenase-1 regulates the progression of K/BxN serum transfer arthritis.

2012

Background Heme oxygenase-1 (HO-1) is induced in many cell types as a defense mechanism against stress. We have investigated the possible role of endogenous HO-1 in the effector phase of arthritis using the K/BxN serum transfer model of arthritis in HO-1 heterozygous and homozygous knock-out mice. Methodology/Principal Findings Arthritis was induced in C57/Black-6 xFVB (HO-1+/+, HO-1+/− and HO-1−/−) mice by intraperitoneal injection of 150 µl serum from arthritic K/BxN mice at days 0 and 2. Blood was collected and animals were sacrificed at day 10. Histological analysis was performed in ankle sections. The levels of inflammatory mediators were measured in serum and paw homogenates by enzyme…

MaleTime FactorsAnatomy and PhysiologyMouseNon-Clinical MedicineArthritislcsh:MedicineEndogenyBiochemistryAntioxidantsMicechemistry.chemical_compoundDrug Discoverylcsh:ScienceMusculoskeletal SystemHemeRegulation of gene expressionMultidisciplinaryEffectorSystems BiologyAnimal ModelsEnzymesDisease ProgressionMedicineMatrix Metalloproteinase 3Inflammation Mediatorsmedicine.symptomResearch ArticleCell typeOsteocalcinRheumatoid ArthritisInflammationModel OrganismsRheumatologymedicineAnimalsBiologyBlood CellsRANK Ligandlcsh:Rmedicine.diseaseArthritis ExperimentalMolecular biologyMice Inbred C57BLHeme oxygenaseDisease Models AnimalGene Expression RegulationchemistryImmunologylcsh:QAnkle JointHeme Oxygenase-1PLoS ONE
researchProduct

Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Regist…

2012

Objective.To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (RA), as derived from an Italian national registry.Methods.The clinical records of 853 adult patients with RA in the GISEA (Gruppo Italiano Studio Early Arthritis) registry were prospectively analyzed to compare drug survival rates and the baseline factors that may predict adherence to therapy.Results.In 2003 and 2004, 324 patients started treatment with adalimumab, 311 with etanercept, and 218 with infliximab. After 4 years, the global retention rate of anti-TNF-α therapy was 42%. Etanercept survival (51.4%) …

MaleTime FactorsHealth StatusArthritisKaplan-Meier EstimateReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptArthritis RheumatoidRandomized controlled triallawRheumatoidMonoclonalReceptorsImmunology and AllergyProspective StudiesRegistriesskin and connective tissue diseasesProspective cohort studyHumanizedAntibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biological Markers; Drug Substitution; Female; Health Status; Humans; Immunoglobulin G; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesPain MeasurementDrug SubstitutionAntibodies MonoclonalMiddle AgedArthralgiaAdalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesSurvival RateItalyRheumatoid arthritisAntirheumatic AgentsBiological MarkersAdalimumab; Drug survival; Etanercept; Infliximab; Adalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Registries; Rheumatology; Immunology; Immunology and AllergyFemalemedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedAntibodiesRheumatologyDrug survivalInternal medicineAdalimumabmedicineHumansSurvival ratebusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabInfliximabSurgeryImmunoglobulin GJointsbusinessTumor Necrosis FactorBiomarkers
researchProduct

Relations between subdomains of physical activity, sedentary lifestyle, and quality of life in young adult men

2018

Purpose To assess the relationship between physical activity (PA) in work, transport, domestic and leisure-time domains (with sitting time included) and health-related quality of life (HRQoL) among young adult men. Methods The long version of IPAQ and SF-36 Health Survey were used to assess PA and HRQoL, respectively, in 1425 voluntary 20 to 40 year old Finnish male participants. Participants were divided into tertiles (MET-h/week): Lowest tertile ( 100 MET-h/week). Results The IPAQ domain leisure-time PA predicted positively the Physical Component Summary (PCS) (β=0.11, 95% CI: 0.06 to 0.16) and Mental Component Summary (MCS) (β=0.11, 95% CI: 0.05 to 0.16) dimensions. Occupational PA predi…

MaleTime Factorselämänlaatu0302 clinical medicineQuality of lifeSITTING TIMEOrthopedics and Sports Medicine030212 general & internal medicineYoung adultFinlandPOPULATIONeducation.field_of_studyexercisepublic healthta3141ta3142ASSOCIATIONSitting timehumanitiesLinear relationshipMETmiehetHEALTHfyysinen aktiivisuusAdultyoung adultsCOUNTRIESmedicine.medical_specialtySF-36PopulationPhysical activitymenPhysical Therapy Sports Therapy and Rehabilitationphysical activeness03 medical and health sciencesYoung AdultSF-36medicineHumansVALIDITYeducationMETAANALYSISSedentary lifestyle030203 arthritis & rheumatologynuoret aikuisetbusiness.industryMORTALITYquestionnaires3126 Surgery anesthesiology intensive care radiologyHealth SurveysACTIVITY QUESTIONNAIRE IPAQCross-Sectional Studiesquality of lifePhysical therapySedentary BehaviorbusinessDemography
researchProduct

Diagnostic Value of Optical Spectral Transmission in Rheumatoid Arthritis: Associations with Clinical Characteristics and Comparison with Joint Ultra…

2020

Objective.To examine the value of optical spectral transmission (OST) in detecting joint inflammation in patients with rheumatoid arthritis (RA) and to evaluate whether OST correlates with certain patient characteristics.Methods.OST measurements were performed in the metacarpophalangeal, proximal intraphalangeal, and wrist joints of 168 patients with RA and 114 controls. OST difference between the 2 groups was statistically examined and subsequently controlled for the effect of possible confounding factors. Diagnostic OST performance was tested by receiver-operating characteristics. Moreover, associations of OST with clinical and serological activity markers (patient group), joint ultrasoun…

MaleWrist Jointmedicine.medical_specialtySpectral transmissionImmunologySeverity of Illness IndexSpearman's rank correlation coefficientArthritis RheumatoidCorrelation03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinemedicineHumansImmunology and Allergy030212 general & internal medicineUltrasonography030203 arthritis & rheumatologySynovitisbusiness.industryfungiUltrasoundConfoundingArea under the curveUltrasonography DopplerAnthropometrymedicine.diseaseRheumatoid arthritisFemalebusinessThe Journal of Rheumatology
researchProduct

Immunomodulatory Mechanisms Mediated by Sex Hormones in Rheumatoid Arthritis

1996

Malebusiness.industryGeneral Neurosciencemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyArthritis RheumatoidReceptors EstrogenHistory and Philosophy of ScienceReceptors AndrogenRheumatoid arthritisImmunologyHumansMedicineFemaleGonadal Steroid HormonesbusinessHormoneAnnals of the New York Academy of Sciences
researchProduct

Reliability, validity and feasibility of nail ultrasonography in psoriatic arthritis

2016

International audience; Objective: To determine the feasibility, reliability and validity of nails ultrasonography in psoriatic arthritis as an outcome measure.Methods: Pilot prospective single-centre study of eight ultrasonography parameters in B mode and power Doppler concerning the distal interphalangeal (DIP) joint, the matrix, the bed and nail plate. Intraobserver and inter-observer reliability was evaluated for the seven quantitative parameters (ICC and kappa). Correlations between ultrasonography and clinical variables were searched to assess external validity. Feasibility was assessed by the time to carry out the examination and the percentage of missing data.Results: Twenty-seven p…

MalecognitionbehaviorsPilot ProjectsNailperceptionfrontotemporal dementia030207 dermatology & venereal diseases0302 clinical medicineProspective StudiesUltrasonographyObserver VariationmechanismsSynovitismedicine.diagnostic_testFeasibilitytoolMiddle AgedNail plateReliability3. Good healthmedicine.anatomical_structure[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemPsoriatic arthritisNail (anatomy)Femalemovementmedicine.symptomAdultmedicine.medical_specialtyPhysical examinationValidity[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemExternal validity03 medical and health sciencesPsoriatic arthritisRheumatologyvisuomotor integrationFinger JointSynovitismedicineHumansAged030203 arthritis & rheumatologybusiness.industryArthritis PsoriaticEnthesitisReproducibility of ResultsapraxiaUltrasonography Dopplermedicine.diseaseSurgeryNailsFeasibility StudiesbusinessNuclear medicineKappaJoint Bone Spine
researchProduct

Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry.

2022

RATIONALE AND OBJECTIVE: There is a dearth of data characterizing patients requiring kidney replacement therapy (KRT) for kidney failure due to systemic lupus erythematosus (SLE) and their clinical outcomes. The aim of this study was to describe trends in incidence and prevalence of KRT among these patients as well as to compare their outcomes to patients treated with KRT for diseases other than SLE.STUDY DESIGN: Retrospective cohort study based on kidney registry data.SETTING & PARTICIPANTS: Patients recorded in 14 registries of patients receiving kidney replacement therapy that provided data to the European Renal Association (ERA) Registry between 1992 and 2016.PREDICTOR: SLE as cause…

Malekidney diseasemedicine.medical_treatmentMAINTENANCE DIALYSIS030232 urology & nephrologyLupus nephritislupus nephritis (LN)0302 clinical medicineLupus Erythematosus Systemickidney replacement therapy (KRT)RegistriesRenal InsufficiencyKidney transplantationRISKeducation.field_of_studyKidneyregistry studyIncidence (epidemiology)IncidenceSTAGE RENAL-DISEASELupus Nephritis3. Good healthEuropeRenal Replacement Therapymedicine.anatomical_structureNephrologySURVIVALFemalemedicine.medical_specialtyprevalencePopulationkidney transplantationUNITED-STATESsurvival03 medical and health sciencesAFRICAN-AMERICAN PATIENTSInternal medicinemedicineHumansESRDeducationNEPHRITISDialysisRetrospective Studies030203 arthritis & rheumatologyProportional hazards modelbusiness.industryTRANSPLANTATIONMORTALITYRetrospective cohort studymedicine.diseasekidney failureend-stage renal disease (ESRD)3121 General medicine internal medicine and other clinical medicineSystemic lupus erythematosus (SLE)Kidney Failure ChronicprognosisbusinessAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
researchProduct

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis : 6-year efficac…

2019

Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA) Methods Patients who completed the 2-year, open-label, phase III CLinical Study In Pediatric Patients of Etanercept for Treatment of ERA, PsA, and Extended Oligoarthritis (CLIPPER) were allowed to enroll in its 8-year long-term extension (CLIPPER2). Children received ETN at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/week. Efficacy assessments included the JIA core set of outcomes, the JIA American College of Rheumatology response criteria (JIA-ACR), and t…

Malelcsh:Diseases of the musculoskeletal systemArthritisCHILDRENCATEGORIESDISEASE-ACTIVITYEtanerceptEtanerceptEnthesitis-related arthritis (ERA)Juvenile Arthritis Disease Activity ScoreDOUBLE-BLINDINITIATIONNECROSIS-FACTORDEFINING CRITERIAMedicine and Health SciencesMedicineChildNon-U.S. Gov'tClinical trial; Efficacy; Enthesitis-related arthritis; Enthesitis-related arthritis (ERA); Etanercept; Extended oligoarticular juvenile idiopathic arthritis (eoJIA); Juvenile idiopathic arthritis; Psoriatic arthritis (PsA); SafetyOligoarthritisResearch Support Non-U.S. Gov'tMETHOTREXATEClinical trialTreatment OutcomeAntirheumatic AgentsChild PreschoolFemaleSafetymedicine.drugResearch Articlemedicine.medical_specialtyAdolescentEfficacyEnthesitis-related arthritisResearch SupportPsoriatic arthritisPsoriatic arthritis (PsA)Internal medicineAdalimumabJournal ArticleHumansetanercept ; juvenile idiopathic arthritis ; enthesitis-related arthritis ; extended oligoarticular juvenile idiopathic arthritis (eoJIA) ; enthesitis-related arthritis (ERA) ; psoriatic arthritis (PsA) ; efficacy ; safety ; clinical trialPEDIATRIC-PATIENTSbusiness.industryJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileOligoarticular Juvenile Idiopathic Arthritislcsh:RC925-935Extended oligoarticular juvenile idiopathic arthritis (eoJIA)businessADALIMUMAB
researchProduct

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

2020

Background: To derive a list of opportunistic infections (OI) through the analysis of the juvenile idiopathic arthritis (JIA) patients in the Pharmachild registry by an independent Safety Adjudication Committee (SAC). Methods: The SAC (3 pediatric rheumatologists and 2 pediatric infectious disease specialists) elaborated and approved by consensus a provisional list of OI for use in JIA. Through a 5 step-procedure, all the severe and serious infections, classified as per MedDRA dictionary and retrieved in the Pharmachild registry, were evaluated by the SAC by answering six questions and adjudicated with the agreement of 3/5 specialists. A final evidence-based list of OI resulted by matching …

Malelcsh:Diseases of the musculoskeletal systemBiologic:Paediatrics: 760 [VDP]Artritis infecciosaMedDRAInfants malaltsArthritisSeverity of Illness IndexHospital patientsCohort StudiesPharmacovigilance0302 clinical medicine030212 general & internal medicineRegistriesChildBiologics; Immunosuppressive therapy; Infections; Juvenile idiopathic arthritis; Opportunisticbiologics ; immunosuppressive therapy ; infections ; juvenile idiopathic arthritis ; opportunisticBarneleddgikt3. Good healthImmunosuppressive therapySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAAntirheumatic AgentsChild PreschoolCohortPediatric Infectious DiseaseFemaleInfectionResearch Articlemedicine.medical_specialtyTuberculosisjuvenil idiopathic arthritisBiologicsOpportunistic InfectionsInfectionsHerpes Zoster03 medical and health sciencesImmunocompromised HostJuvenile idiopathic arthritiInternal medicinePharmacovigilancemedicineHumansTuberculosisbook030203 arthritis & rheumatologyMalalts hospitalitzatsImmunosupressióbusiness.industrySick childrenJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileInfectious arthritis:Pediatri: 760 [VDP]Orthopedic surgeryOpportunistiske infeksjonerbook.journalOpportunisticlcsh:RC925-935businessInfeccions oportunistesImmunosuppression
researchProduct

A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry

2017

Abstract Background Behçet’s disease is a rare multi-systemic inflammatory disease with unknown etiology which involves principally oral and genital mucosa, skin and eyes. Average age at onset of the disease is about 25-30 years, but it may be diagnosed before the age of 16. It is not very rare in Italy, even though there are limited data concerning epidemiology. Aim of this study is to describe the baseline data of an Italian cohort of patients with as having BD or probable BD. Methods We described the baseline data of the first national epidemiological study on children coming from 16 Italian Pediatric Rheumatologic Centers diagnosed by the treating physicians as having Behçet’s Disease. …

Malelcsh:Diseases of the musculoskeletal systemDiagnostic criteriaCross-sectional studyConstitutional symptomsBehcet's diseasePediatricsCohort StudiesBehçet’s diseaseBiological Factors0302 clinical medicineEpidemiologyImmunology and AllergyLongitudinal StudiesRegistries030212 general & internal medicineBehçet’s disease Children Clinical features Diagnostic criteria Treatment Pediatrics Perinatology and Child Health Rheumatology Immunology and AllergyChildChildrenBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Adolescent; Behcet Syndrome; Biological Factors; Child; Cohort Studies; Cross-Sectional Studies; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Italy; Longitudinal Studies; Male; Registries; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and Allergyeducation.field_of_studyBehçet's diseaseBehcet Syndromelcsh:RJ1-570Perinatology and Child HealthItalySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACohortFemaleImmunosuppressive AgentsResearch ArticleCohort studyBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and Allergymedicine.medical_specialtyAdolescentPopulationBehçet's disease03 medical and health sciencesRheumatologyInternal medicinemedicineHumansBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyeducationGlucocorticoids030203 arthritis & rheumatologybusiness.industrylcsh:PediatricsClinical featuresmedicine.diseaseTreatmentCross-Sectional StudiesClinical featurePediatrics Perinatology and Child HealthEtiologylcsh:RC925-935business
researchProduct